- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novartis AG ADR (NVS)
Novartis AG ADR stock price live, this page displays NYSE NVS stock exchange data. View the NVS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Novartis AG ADR real time stock price chart below.
What Is the Novartis AG ADR Stock Price Today?
The Novartis AG ADR stock price today is 162.55.
What Is the Stock Symbol for Novartis AG ADR?
The stock symbol for Novartis AG ADR is "NVS."
What Stock Exchange Does Novartis AG ADR Trade On?
Novartis AG ADR is listed and trades on the NYSE stock exchange.
Is Novartis AG ADR a Good Stock to Buy?
Determining whether Novartis AG ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVS quote. (ISIN: US66987V1098)
What Is the Novartis AG ADR Stock Price Today?
The Novartis AG ADR stock price today is 162.55.
What Is the Stock Symbol for Novartis AG ADR?
The stock symbol for Novartis AG ADR is "NVS."
What Stock Exchange Does Novartis AG ADR Trade On?
Novartis AG ADR is listed and trades on the NYSE stock exchange.
Is Novartis AG ADR a Good Stock to Buy?
Determining whether Novartis AG ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVS quote. (ISIN: US66987V1098)
NYSE
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
159.36
163.11
52 wk Range
123.24
170.46
NVS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
159.36163.11
52 wk Range
123.24170.46
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
154.80
Downside
-4.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 30 consecutive years
Novartis receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Novartis receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Novartis receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy
Analyst Ratings
5 Buy
4 Hold
2 Sell
Ratings:
11 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 154.80
(-4.77% Downside)
Novartis AG ADR Earnings Call Summary for Q3/2026
- Novartis Q3 core EPS of $2.46 beat estimates by 7.9%; revenue of $14.52B missed by 0.55% but grew 4% in constant currency terms.
- Core operating margin expanded 2 points to 41.6% on cost discipline; reported income fell 61% on $1.9B impairment for failed del-desiran trial.
- Priority brands surged 29% led by Kisqali, Kesimpta, Leqvio, Scemblix and Pluvicto, offsetting patent losses from older medicines like Entresto.
- Company raised 2026 core operating income guidance to low double-digit growth from prior low single-digit decline forecast; reaffirmed 5-6% sales CAGR.
- Key catalysts include Q4 remibrutinib FDA submission, ianalumab decision by year-end, ORION-4 Leqvio data, and Rhapsido peak sales raised above $4B.
Last Updated: 10/27/2026, 09:32 PM
Read Full TranscriptEarnings
Latest Release
Oct 27, 2026
EPS / Forecast
2.46 / 2.28
Revenue / Forecast
14.52B / 14.6B
Compare NVS to Peers and Sector
Metrics to compare | NVS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 30.5x | 32.6x | −0.2x | |
PEG Ratio | −1.08 | 0.73 | 0.00 | |
Price/Book | 8.2x | 6.2x | 2.6x | |
Price / LTM Sales | 5.3x | 4.8x | 2.8x | |
Upside (Analyst Target) | −4.8% | 2.0% | 64.8% | |
Fair Value Upside | Unlock | 1.7% | 9.7% | Unlock |
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Novartis ADR (NVS) Stock Price Today?
The Novartis ADR stock price today is 162.55 USD.
What Stock Exchange Does Novartis ADR Trade On?
Novartis ADR is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Novartis ADR?
The stock symbol for Novartis ADR is "NVS."
Does Novartis ADR Pay Dividends? What’s The Current Dividend Yield?
The Novartis ADR dividend yield is 1.9%%.
What Is the Novartis ADR Market Cap?
As of today, Novartis ADR market cap is 306.29B USD.
What Is Novartis ADR's Earnings Per Share (TTM)?
The Novartis ADR EPS (TTM) is 5.26.
When Is the Next Novartis ADR Earnings Date?
Novartis ADR will release its next earnings report on Feb 03, 2027.
From a Technical Analysis Perspective, Is NVS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Novartis ADR Stock Split?
Novartis ADR has split 2 times.
How Many Employees Does Novartis ADR Have?
Novartis ADR has 75267 employees.
What is the current trading status of Novartis ADR (NVS)?
As of Nov 08, 2026, Novartis ADR (NVS) is trading at a price of 162.55 USD, with a previous close of 162.55 USD. The stock has fluctuated within a day range of 159.36 USD to 163.11 USD, while its 52-week range spans from 123.24 USD to 170.46 USD.
What Is Novartis ADR (NVS) Price Target According to Analysts?
The average 12-month price target for Novartis ADR is 154.80 USD, with a high estimate of 185 USD and a low estimate of 130 USD. 5 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an -4.77% Downside potential.
What Is the NVS Premarket Price?
NVS's last pre-market stock price is 159.56 USD. The pre-market share volume is 20,550.00, and the stock has decreased by -2.37, or -1.46%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.